NCT01453426View on ClinicalTrials.gov

Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Healthy
Interventions
DRUG

BG00012 Dose 1

DRUG

BG00012 Dose 2

Trial Locations (2)

Unknown

Research Site, Melbourne

Research Site, Hong Kong

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY